KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that its wholly-owned subsidiary, KalVista Pharmaceuticals, Ltd ...

As KalVista Pharmaceuticals awaits an FDA decision on its hereditary angioedema (HAE) treatment sebetralstat, the company has ...

KalVista Pharmaceuticals has licensed commercialisation rights for sebetralstat, an oral on-demand treatment for hereditary ...

The following is a summary of “Comorbidities in Canadian patients with hereditary angioedema: a quantitative survey study,” ...

KalVista Pharmaceuticals has finished enrolling subjects in its KONFIDENT-KID trial of sebetralstat for hereditary angioedema ...

Hereditary angioedema (HAE) is a rare genetic disorder ... Food triggers were associated with abdominal symptoms or swelling of the face, throat, extremities, or genitals. In both studies ...

Symptoms affecting your nervous system, including seizures, are also common in people with HAE. One study of people with HAE found that around 17% have epilepsy. Hereditary angioedema and dental ...

CM. Read why NTLA stock has potential with upcoming 2025 data and a growing $12B market for Transthyretin Amyloidosis.

CSL Limited's financial performance reveals not just growth but a commitment to future innovations. With a total revenue of $22.2 billion, the company allocated $1.43 billion—approximately 9.6% of its ...

SAN DIEGO — Patients with hereditary angioedema whose attacks impacted ... 10 minutes of onset without prompt administration of treatment, at least once in their lives, the researchers said.

In other recent news, Pharvaris has reported positive long-term data for its oral drug deucrictibant, intended for the treatment of hereditary angioedema (HAE). The CHAPTER-1 Open-Label Extension ...

Treatment depends on the underlying cause ... these compounds can cause the swelling we recognize as angioedema. Hereditary ...